Hook / Thesis
Cohu is back in play after a big year of gains and a sharp mean-reversion move from its 52-week high. The stock trades at $41.84 and is carving a base where industry-level AI demand is still accelerating. The near-term technicals are constructive - a positive MACD histogram and price sitting just above the 10-day SMA - while the underlying industry headlines show robust semiconductor test demand. That combination creates a defined mid-term swing opportunity: buy now with a clear stop and a concrete price target.
My thesis is simple: the market is pricing Cohu as a company that should capture a slice of rising AI and memory test cycles, but recent weakness has reset expectations enough to offer an asymmetric risk/reward. The business still has work to do on profitability, but free cash flow and a sub-$2.0 billion market cap imply limited downside versus the upside if the company converts orders into margin recovery.
What the company does and why the market should care
Cohu makes back-end semiconductor test and handling equipment, interface products, and related services used in chip production. Semiconductor test equipment is a critical bottleneck as hyperscalers and memory makers ramp AI accelerators and HBM (high-bandwidth memory). The market cares because these test cycles are lumpy but high-value - a few large programs can move revenue and margins meaningfully for a small-cap equipment provider.
Facts and figures that matter
- Current price: $41.84; prior close: $40.41.
- Market cap (snapshot): $1,974,195,707.50 - under $2.0 billion.
- 52-week range: $21.10 (low) to $75.72 (high).
- Price-to-sales: 3.36; EV-to-sales: 3.41; EV: $1,943,109,713.
- Free cash flow (most recent): $55,854,000, which implies an approximate FCF yield around 2.8% on current market cap.
- Earnings per share: -$0.48 (negative); trailing P/E is not meaningful.
- Balance sheet / liquidity metrics: current ratio ~ 5.16, quick ratio ~ 4.24 (indicating liquidity buffers).
- Technicals: 10-day SMA $41.714; 20-day SMA $45.545; RSI ~ 40.6 (neutral-to-oversold). MACD histogram slightly positive and listed state as bullish_momentum.
- Short interest: roughly 8.8 million shares recently, with days-to-cover in the high single digits - a data point that can amplify moves in either direction.
Why now?
Industry signals are the proximate catalyst. Peer announcements show very strong test demand for AI accelerators and memory: Teradyne reported an AI-driven surge in test revenues in mid-November (reported 11/13/2026) and competitors are expanding capacity. Separately, market commentary highlights that semiconductor test equipment providers are capturing accelerated order flow from hyperscalers and memory builders. Cohu has been volatile: it gained materially earlier in the year, pulled back from the October high, and now sits at an actionable consolidation band under $42.
Valuation framing
Cohu trades like a growth-equipment supplier priced for a recovery. At a market cap near $1.97 billion and EV-to-sales of 3.41, the company is pricing in significant forward revenue growth and margin normalisation. That premium is juxtaposed against a negative EPS and an elevated EV/EBITDA (~56x), which tells you the market expects earnings to improve materially from current levels.
Look at the positive: free cash flow of $55.85 million provides a real cushion and supports continued R&D/capex to chase AI test programs. The near-term valuation is therefore a forward-looking bet: if Cohu converts booked orders and improves margins, rerating is possible; if it fails to do so, multiples will re-contract quickly given negative EPS and compressed EBITDA.
Catalysts (what will drive the trade)
- Quarterly results or guidance that shows order growth or backlog expansion tied to AI accelerators and HBM programs.
- Public confirmation from a hyperscaler or memory customer of new test contracts that lean on Cohu equipment.
- Evidence of margin improvement (better gross margins or operating leverage) driven by higher volume or product mix.
- Industry peers' confirmations of sustained AI test demand (Teradyne's 11/13/2026 results are an example) that validate the secular trend.
- Reduction in short interest or a meaningful buyback program that supports the share base.
Trade plan - actionable rules
Entry: $41.84 (current).
Stop loss: $36.50 (strict).
Target: $60.00.
Time horizon: mid term (45 trading days) - this is a swing trade intended to capture order-flow / guidance beats and near-term margin improvement as customers ramp AI-related test programs.
Rationale: Entry at $41.84 puts you in around the 10-day SMA with a stop below recent intra-day lows (~$40.02). The target of $60 is below the 52-week high of $75.72 but represents a meaningful rerating that could occur if Cohu converts orders to revenue and begins showing margin leverage. The stop at $36.50 limits downside and respects the company’s support zone while giving the trade room for short-term volatility.
Risk management and position sizing
This is a medium-risk swing trade. Keep the position size such that a stop loss to $36.50 equals no more than 1-2% of portfolio risk. Consider trimming on headlines or if the stock moves >20% toward the target on elevated volume—short-interest-driven squeezes can create volatile moves on both directions.
Risks and counterarguments
- Profitability remains uncertain. Cohu reports negative EPS (most recent -$0.48) and carries an EV/EBITDA north of 50x. If revenue growth lags, the stock can re-rate lower quickly.
- Competition and market share risk. Larger competitors like Teradyne or well-funded peers could take share or undercut pricing, pressuring margins.
- Customer concentration and timing. Test equipment demand is program-driven; if hyperscaler ramps slip or programs are delayed, revenue recognition can be pushed out and expectations will be punished.
- High short interest amplifies volatility. With ~8.8 million shares short and days-to-cover in the high single digits, the stock can gap sharply on either positive or negative news.
- Valuation dependency on forward improvement. Current multiples imply improvement in EBITDA and earnings; failure to deliver will magnify downside because trailing profitability is weak.
Counterargument: Analysts and some peer comparisons have flagged that FormFactor (FORM) may be a cleaner way to play AI test demand given stronger profitability and freshly upgraded estimates. Estimates for Cohu have deteriorated recently (some sell-side commentary trimmed forward EPS), and a cautious investor could argue capital is better allocated to a more profitable peer or to wait for a clearer earnings inflection before buying Cohu.
How this trade can go wrong
If Cohu reports weak backlog or guides below investor expectations, or if industry customers delay qualification of new test programs, the stock can revisit the $30s quickly. Also, any major order wins by larger competitors could shift market share narratives against Cohu and produce a re-rating.
Conclusion and what would change my mind
I am constructive and rate this a buy for a controlled mid-term swing: entry at $41.84, stop at $36.50, target $60 over ~45 trading days. The upside is the stock rerating on meaningful AI test demand translating into revenue and margin recovery; the downside is failure to execute on book-to-bill and profit improvement given current negative EPS and high multiples.
I would change my view to neutral or bearish if any of the following occur: (1) company issues guidance materially below consensus or discloses lost or delayed key AI-related contracts; (2) quarterly free cash flow turns sharply negative without a clear capex plan; or (3) short interest rises materially and is paired with worsening fundamentals that create forced selling pressure.
Bottom line: Cohu is a classic recovery-as-a-trade: the macro tailwind of AI test demand is real, and the pullback has created a defined risk/reward. Execute with a strict stop, monitor order/backlog commentary closely, and be ready to exit or trim on either sharp outperformance or disappointing guidance.